Media

PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli

Posted: Feb 06, 2025

PharmAla Issues Q1 Financial Statements

Posted: Jan 29, 2025

PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel

Posted: Jan 20, 2025

PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement

Posted: Dec 20, 2024

PharmAla Announces Private Placement

Posted: Dec 13, 2024

PharmAla Reaches Agreement In Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License

Posted: Nov 14, 2024

PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

Posted: Nov 07, 2024

PharmAla to supply the Icahn School of Medicine with LaNeo MDMA

Posted: Oct 21, 2024

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA

Posted: Oct 08, 2024

PharmAla contracted to supply McLean Hospital with LaNeo MDMA

Posted: Oct 02, 2024

PharmAla to supply Johns Hopkins Medicine for Clinical Trial

Posted: Sept 11, 2024

PharmAla Launches MDMA Clinical Trial Tool for Researchers

Posted: Aug 22, 2024

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

Posted: Aug 09, 2024

PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement

Posted: Jul 30, 2024

CEO Letter To Shareholders

Posted: Jun 06, 2024

PharmAla CEO Nick Kadysh Pens Op-ed: Mental Health in Crisis, MDMA May Be the Prescription

Posted: May 23, 2024

PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

Posted: May 03, 2024

PharmAla Closes Private Placement and Concurrent Debt Settlement

Posted: Apr 19, 2024

Cortexa Commences Manufacturing GMP LaNeo™ MDMA In Australia

Posted: Apr 05, 2024

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Posted: Mar 26, 2024

PharmAla Biotech Signs Sale Agreement with Numinus

Posted: Mar 26, 2024

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Posted: Mar 20, 2024

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’S Authorized Prescriber Scheme

Posted: Mar 18, 2024

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Posted: Mar 08, 2024

PharmAla named an Intellectual Property Ontario Client

Posted: Feb 22, 2024

PharmAla Data to be Published in ACS Chemical Neuroscience

Posted: Feb 20, 2024

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

Posted: Feb 09, 2024

PharmAla Biotech Annual General Meeting Materials

Posted: Feb 06, 2024

PharmAla releases Q1 Interim Financial Statement and Business Update

Posted: Jan 31, 2024

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

Posted: Jan 25, 2024

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Posted: Jan 24, 2024

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Posted: Jan 08, 2024

PharmAla Files Audited Financials for Year Ending August 31, 2023

Posted: Dec 29, 2023

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Posted: Nov 15, 2023

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

Posted: Nov 09, 2023

PharmAla Partners with Clariti Strategic Advisors™

Posted: Nov 08, 2023

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Posted: Nov 07, 2023

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Posted: Sept 25, 2023

CEO Letter to Shareholders

Posted: Sept 11, 2023

PharmAla Begins Trading on OTCQB

Posted: Sept 06, 2023

PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute

Posted: Aug 10, 2023

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Posted: Jul 31, 2023

PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

Posted: Jul 20, 2023

Cortexa Makes First Drug Order for Australian Commercial Market

Posted: Jul 04, 2023

Offering Document under the Listed Issuer Financing Exemption

Posted: Jun 13, 2023

PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000

Posted: Jun 12, 2023

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

Posted: Jun 12, 2023

PharmAla Awarded Research Grant by Ontario Centre for Innovation

Posted: Jun 09, 2023

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Posted: May 16, 2023

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

Posted: May 01, 2023

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

Posted: Apr 25, 2023

PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA

Posted: Apr 20, 2023

PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules

Posted: Apr 11, 2023

PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences

Posted: Mar 01, 2023

PharmAla Biotech Completes Annual General Meeting

Posted: Feb 28, 2023

CEO Letter to Shareholders

Posted: Feb 28, 2023

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Posted: Feb 23, 2023

PharmAla Biotech closes purchase order with Emyria Ltd., completes filing of “LaNeo” trademark in Australia

Posted: Feb 14, 2023

Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change

Posted: Feb 03, 2023

PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA

Posted: Jan 24, 2023

PharmAla Completes Pre-IND Meeting with FDA, to present at KCSA Virtual Investor Conference

Posted: Dec 13, 2022

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Posted: Nov 16, 2022

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Posted: Nov 02, 2022

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Posted: Oct 13, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Posted: Oct 11, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Posted: Oct 06, 2022

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

Posted: Oct 05, 2022

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

Posted: Aug 31, 2022

PharmAla Biotech completes filing of patent application for 6 MDMA analogs

Posted: Aug 29, 2022

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Posted: Aug 22, 2022

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Posted: Aug 15, 2022

PharmAla Biotech Applauds Sen. Cory Booker and Sen. Rand Paul's Bill to Include MDMA in "Right-to-Try" Legislation

Posted: Aug 04, 2022

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Posted: Jul 04, 2022

PharmAla Biotech Registers Trademark for MDMA

Posted: Jun 24, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Posted: Jun 02, 2022

Psychedelics Canada Announces The Launch Of The First National Trade Association For Legal Psychedelics Companies

Posted: May 27, 2022

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

Posted: May 19, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Posted: May 10, 2022

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

Posted: Apr 09, 2022

PharmAla Biotech adds David Purcell as Director of Sales

Posted: Mar 14, 2022

PharmAla Biotech contracts with InterVivo Solutions to validate novel MDMA analogs

Posted: Mar 07, 2022

Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech

Posted: Feb 10, 2022

PharmAla Biotech initiates research at the University of Arkansas for Medical Sciences

Posted: Jan 17, 2022

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

Posted: Jan 10, 2022